Roxadustat

證據等級: L5

預測適應症: 4 個

Roxadustat: From Anemia of Chronic Kidney Disease to Dry Eye Syndrome

One-Sentence Summary

Roxadustat is a HIF-PH (hypoxia-inducible factor prolyl hydroxylase) inhibitor globally approved for anemia associated with chronic kidney disease. The TxGNN model predicts it may also be effective for dry eye syndrome, but this direction is currently supported by only 1 clinical trial and no publications, so the evidence base is still very early.

Quick Overview

Item	Content
Original Indication	Not available in the evidence pack (no local licenses on file); globally, roxadustat is approved for anaemia associated with chronic kidney disease
Predicted New Indication	Dry eye syndrome
TxGNN Prediction Score	99.51%
Evidence Level	L3 (single observational study, no completed RCT)
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, roxadustat is a HIF-PH inhibitor used for anemia associated with chronic kidney disease (CKD), and mechanistically may be applicable to dry eye syndrome.

Renal anemia and dry eye syndrome are not obviously linked at first glance, but the one identified clinical trial (NCT06287879) offers a plausible bridge: it examines meibomian gland structure and function specifically in renal anemia patients treated with erythropoietin or roxadustat who present with dry eye symptoms. This suggests a possible connection between chronic anemia/hypoxia physiology (or its treatment) and ocular surface / meibomian gland health, which may be what the TxGNN model is picking up on.

However, this trial is observational and descriptive (it characterizes meibomian gland findings in an existing patient population) rather than an interventional study testing roxadustat's therapeutic effect on dry eye. The mechanistic pathway from HIF stabilization to ocular surface benefit has not been established, so the prediction should be treated as hypothesis-generating rather than confirmed.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06287879	NA	Unknown	50	Observational study characterizing meibomian gland function and morphology in renal anemia patients (treated with EPO or roxadustat) presenting with dry eye symptoms

Literature Evidence

Currently no related literature available.

Finland Market Information

Roxadustat is not currently marketed in Finland — no marketing authorizations are on record (0 licenses).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for the dry eye syndrome indication rests on a single observational trial of unknown status with no supporting literature, and the drug is not yet marketed in Finland. Critically, TFDA/Fimea package insert warnings and contraindications are flagged as a Blocking data gap, which prevents even an initial safety (S1) assessment.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — Blocking gap
Confirmed mechanism of action (MOA) documentation from DrugBank
Drug-drug interaction (DDI) data (currently not found)
Follow-up on NCT06287879 to determine its completion status and results
At least one interventional/controlled study directly testing roxadustat for dry eye syndrome before advancing beyond hypothesis stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.